Conclusion
RA
EVENTS
The evidence of effect is inconclusive for the efficacy outcomes, although the data showed a trend toward clinical efficacy. Our findings could suggest that MSCs therapy could be considered in treating RA when first-line treatment of RA as conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs) treatments have failed, and a biologic DMARDs is not feasible. Overall, a favorable safety profile and no life-threatening events were observed in subjects with RA. However, due to the methodological limitations of the included studies and the considerable heterogeneity between there, several high-quality, large sample sizes and extended follow-up RCTs should be performed to confirm the trend toward clinical efficacy observed in this study.